| Name | Title | Contact Details |
|---|
Tarrytown Expocare Pharmacy is a specialized long-term care pharmacy dedicated to serving individuals with intellectual and developmental disabilities (IDD) and behavioral health needs. The company operates across 30 U.S. states with ten physical locations, providing institutional pharmacy services to group homes, foster families, and residential care facilities. Tarrytown Expocare focuses on efficiency and safety, offering innovative solutions like color-coded blister packs to simplify medication administration. The pharmacy provides a range of services, including medication management, clinical collaboration, compliance support, and ongoing training for caregivers and nurses. Their secure online portal allows for 24/7 access to manage prescriptions and care coordination. Tarrytown Expocare emphasizes person-centric care and regulatory compliance, aiming to improve outcomes for vulnerable populations through reliable medication delivery and collaborative pharmacy solutions.
Ibidi is a Verona, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
EMD Biosciences, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Batu Biologics is a biotechnology-based pharmaceutical company focused on the development and commercialization of novel therapies that target the “Achilles Heel of Cancer:” the tumor blood vessels. Batu’s flagship therapeutic, ValloVax™, is an angiogenesis targeting cancer vaccine in the late stages of preclinical development. Batu Biologics plans to file an Investigational New Drug (IND) application for ValloVax in Q1 of 2015, seeking clinical approval to treat patients with lung cancer.
Oncobiologics, Inc. has changed its name to Outlook Therapeutics, Inc. Outlook Therapeutics is a clinical-stage biopharmaceutical company focused on developing its lead clinical program, ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (wet AMD). ONS-5010 is currently in its first clinical trial, which is being conducted outside of the U.S. and is designed to serve as the first of two adequate and well controlled studies for wet AMD.